Australia’s TGA approves Mylan/Alphapharm’s Abevmy® (biosimilar bevacizumab)

Sep 6, 2021

Australia’s TGA approved Mylan/Alphapharm’s Abevmy® (biosimilar bevacizumab) for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube, peritoneal cancer and cervical cancer.

Print Page Mail Article